Board of Trustees of the Leland Stanford Junior University

1. Biogen, Inc. $9,299,516 66 payments
2. Blueprint Medicines Corporation $5,696,561 518 payments
3. Genentech, Inc. $4,355,957 224 payments
4. Hoffmann-La Roche Limited $2,639,519 176 payments
5. Regeneron Pharmaceuticals, Inc. $2,590,576 367 payments
6. Genmab A/S $2,264,099 564 payments
7. Innate Pharma, Inc $1,718,779 74 payments
8. Novartis Pharmaceuticals Corporation $1,527,797 38 payments
9. F. Hoffmann-La Roche AG $1,509,448 74 payments
10. Genzyme Corporation $1,449,815 83 payments

1. A Phase 1b/2, Open-Label, Safety and Efficacy Study of Epcoritamab (GEN3013; DuoBody-CD3 X CD20) in Relapsed/Refractory Chronic Lymphocytic Leukemia. $2,238,089 557 payments
2. A 3-Part, Randomized, Double-Blind, Placebo-Controlled Phase 2 Study to Evaluate Safety and Efficacy of Avapritinib (BLU-285), a Selective KIT Mutation-Targeted Tyrosine Kinase Inhibitor, in Indolent and Smoldering Systemic Mastocytosis With Symptoms Inadequately Controlled With Standard Therapy $2,232,946 153 payments
3. An Open-label, Single Arm, Phase 2 Study to Evaluate Efficacy and Safety of Avapritinib (BLU-285), A Selective KIT Mutation-targeted Tyrosine Kinase Inhibitor, in Patients With Advanced Systemic Mastocytosis $1,802,679 169 payments
4. A Phase 1 Multiple-Ascending-Dose Study to Assess the Safety,Tolerability, and Pharmacokinetics of BIIB105 Administered Intrathecally to AdultsWith Amyotrophic Lateral Sclerosis With or Without Poly-CAG Expansion in theAtaxin-2 Gene $1,501,274 3 payments
5. Study of IPH2201 (Monalizumab) and Cetuximab in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck $1,383,992 53 payments
6. Phase I, Open-Label, Dose Comparison Study of Avxs-101 for Sitting But Non-Ambulatory Patients With Spinal Muscular Atrophy $1,183,849 30 payments
7. Morpheus Breast Cancer $1,040,746 92 payments
8. A Long-Term Extension Study of Nusinersen (BIIB058) Administered at Higher Doses in Participants With Spinal Muscular Atrophy Who Previously Participated in an Investigational Study with Nusinersen. $812,775 4 payments
9. A Study for Participants With Spinal Muscular Atrophy (SMA) Who Previously Participated in Nusinersen (ISIS 396443) Investigational Studies. $811,459 3 payments
10. Morpheus Breast $794,602 41 payments

1. Patient care $694,460 52 payments
2. Other $231,934 27 payments
3. Overhead $67,534 18 payments
4. Non-patient care $4,704 12 payments
5. Medical research writing or publication $990 3 payments

Only reported on some payments, and a payment can report more than one category, so these amounts overlap.